



REPUBLIC OF KOSOVO - REPUBLIKA KOSOVA - REPUBLIC OF KOSOVA	
QEVERIA E KOSOVO - VLADA KOSOVA - GOVERNMENT OF KOSOVA	
MINISTRIA E SHENDETESISE - MINISTARSTVO ZDRAVLJA - MINISTRY OF HEALTH	
Nësitë Org. Org. Jedinica Org Unit	01
Nr. Prot. Drej. Prot. Prot No	05-1572/2
Nr. i faqeve Drej. Stranica Date	-05- 18, 03, 13 20
Prishtinë, Li	

## Confidentiality Agreement

between

**the Medicines and Healthcare products Regulatory Agency of the United Kingdom of Great Britain and Northern Ireland**

and

**the Ministry of Health of the Republic of Kosovo**

### Introduction

1. The Medicines and Healthcare products Regulatory Agency of the United Kingdom of Great Britain and Northern Ireland (UK) (the MHRA) and the Ministry of Health of the Republic of Kosovo (the Ministry) (acting for an on behalf of the Kosovo Medicines Agency (the KMA)) are the regulatory authorities (collectively, the Participants) with responsibility in their respective countries for the authorisation, granting, renewal, variation, suspension, and revocation of licences, certificates, or other regulatory mechanisms relating to those medicinal products and medical devices for human use which are clinically investigated, marketed, supplied, manufactured, or assembled in the UK and Kosovo respectively.
2. The MHRA acknowledges that the Ministry is authorised, subject to relevant data protection requirements, to exchange information and documentation relating to medicinal products and medical devices in accordance with the domestic laws under which it is constituted.

3. The Participants consider that from time to time circumstances will arise where sharing information held by one regulatory authority will assist the other regulatory authority in carrying out its regulatory functions in relation to medical devices or to ensure the safety, quality, and efficacy of medicinal products for human use which are under clinical investigation, authorised for marketing, or under review for marketing authorisation in both the UK and Kosovo or unilaterally recognised by the Ministry as laid down in a Normative Act issued by the Ministry.
4. The MHRA will co-operate with the Ministry to facilitate the sharing between the Ministry and the MHRA of otherwise non-public documents and information for the purposes of assisting the MHRA in carrying out its functions. This agreement sets out a co-operation and framework understanding of the information which the Ministry and the MHRA may share with each other and the basis upon which they may share it. Non-public documents or information means any document or information not in the public domain that is held by a Participant and is treated as confidential by that Participant in accordance with the domestic laws applicable to the Participant.
5. In this Confidentiality Agreement, the term "medicinal products for human use" excludes all medicinal products subject to evaluation or authorised by the European Medicines Agency (EMA) under the centralised procedure as well as medicinal products authorised at national level by European Union Member States that are subject to official European Union arbitration and referrals.

#### **Information that may be shared between the MHRA and the Ministry**

6. The type of information that may be shared between the regulatory authorities includes, but is not limited to:
  - I. Post-authorisation pharmacovigilance data held by one Participant which raises safety concerns about a product manufactured or distributed in the territory of the other authority.
  - II. Information on quality defect or product recalls held by one Participant in relation to medicinal products and medical devices which are distributed or have been manufactured in the territory of the other Participant.
  - III. Information contained in marketing authorisation applications and applications to vary a marketing authorisation received by one Participant which are of significant public health interest to the other Participant to which they are disclosed.
  - IV. Information contained in reports on inspections done by one Participant which are of significant public health interest to the other Participant to which they are disclosed.
7. The Participants, their officials or representatives, may in their absolute discretion limit the scope of the above information, particularly if its dissemination or

exchange may harm the commercial interests of a third party, breach a duty of confidence or privacy attaching to the information, disclose a trade secret, or be contrary to the public interest or the interests of the Participant. In some cases, exchange of information under this agreement may be subject to prior consent from the companies or individuals concerned.


**The basis on which this information is shared between the Ministry and the MHRA**

8. The Participants recognise that it is an essential element of this agreement that confidential information emanating from one Participant to the other will continue to be treated as such by the receiving Participant, and that so far as practicable and to the extent permitted by its respective laws, the receiving Participant will keep the information exchanged confidential.
9. The MHRA acknowledges that some of the information it will receive from the Ministry may include non-public information exempt from public disclosure under the relevant laws and regulations of Kosovo, such as confidential information, commercially sensitive information, trade secrets, personal information, law enforcement information, or internal pre-decisional information. The MHRA understands that this non-public information is shared in confidence with it, and that the Ministry considers it critical that the MHRA maintain the confidentiality of this information. The MHRA understands that the Ministry will advise the MHRA of the non-public status of the information at the time that the information is shared.
10. The MHRA understands that the Ministry affirms that the Ministry has the authority to protect such non-public information provided to it (including its officials and representatives) by the MHRA, and that it will protect such information as information not to be disclosed by it under the relevant Kosovo legislation. The MHRA considers it crucial that such non-public information should not be disclosed without the consent of the MHRA and that disclosure made without such consent could endanger the international relations between the Participants and seriously jeopardise any further scientific and regulatory interactions between the Ministry and the MHRA.
11. The MHRA understands that the Ministry is of the view that the disclosure by the MHRA of any non public information provided to it (including its officials and representatives) by the Ministry could seriously jeopardise any further scientific and regulatory interactions between the Ministry and the MHRA and would prejudice the international relations between the MHRA and the Ministry. The MHRA understands that the Ministry considers that it is crucial that this non-public information is protected from disclosure and that the condition of sharing this non-public information with the MHRA is that it be held in strict confidence by the MHRA.
12. The MHRA affirms that it has the authority to protect non-public information, including confidential commercial information, provided to its officials or representatives by the Ministry and will take all practicable steps to protect any

### **Duration, change, and termination of Agreement**

18. This agreement will come into effect on signature. It is intended to replace any previous similar agreement between the Participants and will continue in effect until terminated by either Participant on 30 days written notice to the other Participant or if mutually decided by the Participants at any time.
19. The Participants may amend this Agreement at any time by mutual decision in writing.

Date: 11 / 3 / 13

A handwritten signature in cursive script that reads "Kent Woods". The signature is written in black ink and is positioned above a horizontal line.

**Sir Kent Woods**  
Chief Executive  
Medicines and Healthcare products Regulatory Agency